| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Feb 13, 2020Universities awarded $250,000 research grants as part of the CSL Behring-Science Center Research Acceleration Initiative
Universities awarded $250,000 research grants as part of the CSL Behring-Science Center Research Acceleration Initiative 13 Feb 2020 PHILADELPHIA – February 13, 2020 – Researchers at the...
-
Feb 11, 2020CSL Behring advances Ig clinical trial program to address unmet need in treating serious autoimmune disease
KING OF PRUSSIA, Pa.– February 11, 2020 – Global biotherapeutics leader CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted Privigen® (Immune Globulin...
-
Jan 21, 2020This year’s rankings based on independent survey of more than 60,000 U.S. employees across industries
KING OF PRUSSIA, Pa., 21 January 2020 – Forbes Magazine today named CSL Behring among its Best Employers for Diversity 2020. The annual rankings, which measure diversity across six different...
-
Jan 10, 2020
Melbourne, Australia 10 Jan 2020 Melbourne researchers have determined the molecular basis for how an important component of the immune system, called gamma-delta T cells, detects infections and...
-
Jan 9, 2020Chief Executive Officer and Managing Director Paul Perreault will present the company's overview on Monday, January 13, at 3:30 p.m. PT, (6:30 p.m. ET), at the Westin St. Francis Hotel.
King of Prussia, Pa. 09 Jan 2020 Global biotechnology giant CSL Limited, parent company of biotherapeutics leader CSL Behring and world-leading influenza provider Seqirus, will present at the 38th...
-
Dec 9, 2019First and only subcutaneous immunoglobulin (SCIg) approved for maintenance therapy in CIDP qualifies for marketing exclusivity
KING OF PRUSSIA, Pa.– December 9, 2019 – Global biotherapeutics leader CSL Behring announced today that Hizentra received orphan-drug exclusivity from the U.S. Food and Drug Administration...
-
Dec 4, 2019Unique portfolio mix of plasma, cell and gene therapy, recombinant proteins and antibody assets highlighted at Research & Development Briefing
Sydney, Australia 04 Dec 2019 CSL Limited (ASX:CSL; USOTC:CSLLY) is steadily advancing its Research & Development (R&D) pipeline and capabilities to deliver a highly differentiated product...
-
Oct 23, 2019Top 100 CEO rankings based on financial performance as well as environmental, social, and governance (ESG) ratings
KING OF PRUSSIA, Pa. – 23 October 2019 – Harvard Business Review (HBR) today named CSL Limited CEO and Managing Director Paul Perreault among the Top 100 Best Performing CEOs in the world for...
-
Sep 27, 2019• Focuses on Patients Through Disease Awareness Support Activities
MADRID, Spain – 27 September 2019 – Global biotherapeutics leader CSL Behring will host a patient-focused symposium about Alpha 1 Antitrypsin Deficiency (AATD) on Monday, 30 September, during the
-
Jul 1, 2019- Novel real world evidence for AFSTYLA® [Antihemophilic Factor (Recombinant), Single Chain] and IDELVION® ® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein] to be highlighted
Melbourne, Australia - 1 July 2019 - Global biotherapeutics leader CSL Behring announced today that the company will support the presentation of new data from its recombinant coagulation factor...